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Prostate-specific RNA aptamer: 
promising nucleic acid antibody-
like cancer detection
Karina Marangoni1,2, Adriana F. Neves3, Rafael M. Rocha4, Paulo R. Faria5, Patrícia T. Alves2, 
Aline G. Souza2, Patrícia T. Fujimura2, Fabiana A. A. Santos2, Thaise G. Araújo2, 
Laura S. Ward1 & Luiz R. Goulart2,6
We described the selection of a novel nucleic acid antibody-like prostate cancer (PCa) that specifically 
binds to the single-stranded DNA molecule from a 277-nt fragment that may have been partially 
paired and bound to the PCA3 RNA conformational structure. PCA3-277 aptamer ligands were 
obtained, and the best binding molecule, named CG3, was synthesized for validation. Aiming to 
prove its diagnostic utility, we used an apta-qPCR assay with CG3-aptamer conjugated to magnetic 
beads to capture PCA3 transcripts, which were amplified 97-fold and 7-fold higher than conventional 
qPCR in blood and tissue, respectively. Histopathologic analysis of 161 prostate biopsies arranged in 
a TMA and marked with biotin-labeled CG3-aptamer showed moderate staining in both cytoplasm 
and nucleus of PCa samples; in contrast, benign prostatic hyperplasia (BPH) samples presented 
strong nuclear staining (78% of the cases). No staining was observed in stromal cells. In addition, 
using an apta-qPCR, we demonstrated that CG3-aptamer specifically recognizes the conformational 
PCA3-277 molecule and at least three other transcript variants, indicating that long non-coding 
RNA (lncRNA) is processed after transcription. We suggest that CG3-aptamer may be a useful PCa 
diagnostic tool. In addition, this molecule may be used in drug design and drug delivery for PCa 
therapy.
Aptamers are short nucleic acids that fold into a well-defined three-dimensional structure enabling their 
interaction with molecules with high affinity and specificity1. They are considered a novel promising 
class of compounds with diagnostic and therapeutic potentials that may substitute antibodies, which 
larger molecules, greater immunogenicity and peptidase susceptibility limit their pharmacological value2.
SELEX (Systematic Evolution of Ligands by EXponentional enrichment) is the technology used for 
in vitro selection of aptamers3,4, evolving ligands against single molecules to complex target mixtures, or 
even whole organisms. Other targets, such as RNA, have only been used to improve the understanding 
of RNA–RNA interactions5. The most competitive aptamers can participate in complex regulatory net-
works, not only by Watson–Crick interactions with other RNA, but also by forming discrete secondary 
structures that are able to bind DNA6, RNA or protein targets7.
Aptamer specificity and affinity targeting RNA secondary structure is higher than that of complemen-
tary oligonucleotides8. Interesting effects of aptamers, either degrading RNA or inhibiting RNA functions 
have been reported, suggesting their potential role as therapeutic agents targeting long non-coding RNAs 
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(lncRNAs). In addition, some aptamers may be used to modulate viral gene expression by interacting 
with viral RNAs9.
Non-coding RNAs (ncRNAs) fall in a broad range of regulatory RNA molecules such as ribozymes, 
antisense, small interfering RNAs or aptamers that are either naturally found in several cell types or 
artificially designed to target genes and control their expression10. Most lncRNAs, yet to be thoroughly 
characterized, exhibit significant cell type-specific expression, subcellular compartments localization, and 
are associated with human diseases11. Among the many putative regulatory paradigms of these mole-
cules, they may serve as structural RNAs that will be part of the formation of RNA–protein or RNA–
RNA complexes12, which may be critical in regulating the activity or localization of proteins, or serve as 
organizational frameworks of subcellular structures.
As a proof-of-concept for structural ncRNAs, we investigated the lncRNA prostate cancer antigen 
3 (PCA3). This transcript is overexpressed in more than 95% of primary prostate cancer (PCa) tissue 
specimens13 and is the first PCa specific biomarker described14, being involved in PCa cell survival and 
modulation of androgen receptor (AR) signaling15. An in silico analysis generated a remarkable ter-
tiary structure of PCA3 transcript with a significant free energy, showing many hairpins and loops due 
to extensive base pairing within the molecule. Our hypothesis was that this conformational structure 
could be functional and required either for editing or processing, eventually controlling other genes, as 
previously described15. It is interesting to point out that functional RNAs have a more stable secondary 
structure than expected by chance, since most known functional RNAs depend on a defined secondary 
structure16.
High affinity aptamer ligands to PCA3 transcript can also serve as templates for real-time PCR (qPCR), 
possibly to improving PCa diagnosis. The assay format coined as real-time apta-PCR (apta-qPCR) is an 
extension of immuno-PCR17, where the DNA-labeled antibody is replaced by a non-labeled aptamer, 
which, in turn, acts both as a reporter and as biorecognition molecule. Whilst offering great sensitivity, 
immuno-PCR technique suffers from some important drawbacks, such as difficulties in labeling the anti-
body with nucleic acids. Furthermore, this binding lacks precision due to an uneven number of oligos per 
antibody, resulting in high error rates18. Apta-qPCR overcomes the aforementioned limitations, further 
highlighting the exquisite advantages of aptamers.
Our investigation describes the selection of a novel nucleic acid antibody-like for the PCA3 detection, 
an RNA aptamer that specifically binds to the single-stranded DNA molecule from a 277-nt fragment 
that may have been partially paired and bound to the PCA3 RNA conformational structure. We selected 
six ligands to the lncRNA conformational structure with high affinity to the molecule, which were fur-
ther characterized and applied in several assay formats with significant implication for the PCa diagnosis. 
Finally, CG3-aptamer applicability was validated using a tissue microarray, and also by magnetic capture 
followed by qPCR (apta-PCR) in both tissue and peripheral blood, under physiological conditions, with-
out controlling hybridization parameters.
Results
Aptamers that recognize RNA conformational structures. Our in silico analysis of the PCA3 tran-
script generated a remarkable tertiary structure with a highly significant free energy (Δ G > − 975.60 kcal/mol), 
showing an extensive base pairing within the molecule that led to a very constrained structure with many hair-
pins and loops (Fig. 1). We successfully generated a genomic library amplified by PCR after eight rounds of in 
vitro selection against the single-stranded DNA molecule from a 277-nt fragment that may have partially been 
Figure 1. Structure prediction analyses for PCA3 transcript. Insets (red squares) indicate the regions that 
encompass the 277-nucleotide transcript within PCA3. Conformational changes of PCA3 target site and its 
putative interaction with CG3-aptamer, according to StarMir prediction based-pairing.
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paired and bound to the PCA3 RNA conformational structure. Genomic SELEX allowed the identification of 
RNA fragments that might reflect natural interactions with the chosen target.
The selection steps were continuously performed at 37 °C. The PCR product resulted from 1st, 3th and 
8th rounds were cloned and sequenced. Clone sequences were aligned and consensus motifs were identi-
fied using the Clustal software package of the GCG suite of molecular biology programs.
The search for motifs is a strategy to establish a convergent evolution of RNA molecules during selec-
tion in order to identify the most significant and repetitive short nucleotide sequences. Sequences were 
classified according to the presence of five different motifs identified (CCAU, CCCA, UCCA, UGCC and 
UGUC) during the 1st, 3th and 8th selection rounds. Some sequences presented more than one motif, thus 
they appeared in more than one family classification. Sequence alignment demonstrated that the four 
motifs (CCAU, CCCA, UCCA and UGCC) presented one common “CC” dinucleotide repeat (Fig. 2A). 
Heterogeneity of motifs among SELEX rounds were observed, but variability within each round was low 
(Fig. 2B). The CCCA, UGCC and UGUC motifs were the most frequent in the 3th and 8th round, and 
screening led us to the selection of 88 out of 123 valid sequences from the last round.
Sequences smaller than 21 nucleotides were excluded from the analysis. Our results showed that the 
average sequence length dropped from 66 bases to an average 47 bases upon initial transcription and 
reverse transcription in the first selection round, and steadily declined in remainder selection rounds, 
achieving approximately 21 bases at the 8th round (Fig.  2C). More than half of the sequences were 
excluded in the trimming and alignment processes by in silico analyses (48 out of 88 clones).
The free energy minimization between the secondary structure target (PCA3) and aptamers was pre-
dicted by RNAhybrid, as an extension of the classical RNA secondary structure prediction algorithm19 
for two sequences. The established algorithm computes the optimal folding and a set of suboptimal fold-
ings20. To identify potential sites with a stable hybrid, we used a threshold of Δ Ghybrid ≤ − 18 kcal/mol 
as a measure of hybrid stability, and only six sequences (out of 40) were specific to PCA3-277. It is inter-
esting to observe that the predicted hybridization regions between aptamers and PCA3-277 presented 
two conserved binding domains in PCA3-277, located at the positions 2 to 26 and from 186 to 218 bases, 
corresponding to exons 1 and 3, respectively (Table 1).
The structure predictions exhibited two types of conserved domains; one that formed structural scaf-
folds, and another that was frequently represented by single-stranded or non-canonical base-pairing that 
directly interacted with the target molecule20. Results presented in Table 1 show that the CG3-aptamer 
presented more bases paired with a PCA3-277 loop, with a binding energy of Δ Ghybrid = − 19.8 kcal/mol 
(Fig. 1).
Finally, to demonstrate whether PCA3-277 is in fact a linear or conformational structure, we per-
formed binding assays with denatured and native RNA molecules by dot-blot (solid-phase), immuno-
histochemistry, and by magnetic capture in solution. Dot-blot assays were not effective due to baking 
and UV cross-linking procedures, which may have disturbed the native structure. The other assays, 
performed under physiological conditions, have successfully resulted in positive detection only of the 
native folded structure. The binding of aptamers (CG3 and BC4) to the denatured PCA3 RNA, heated 
Figure 2. (A) Sequence alignments of motifs from the 8th selection round. Five motifs were identified 
(CCAU, CCCA, UCCA, UGCC and UGUC) within the best six aptamers (*). Frequencies of selected motifs 
(B) and sequence sizes (C) for 1015 random-sequence pools, across the 1st, 3rd and 8th selection cycles.
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at 97 °C for 5 min, could not capture the molecule, resulting in negative results after PCR amplification 
assays. If PCA3 molecules had been bound to the aptamers, they would have been eluted by the alkaline 
treatment prior to PCR amplification, and results would be positive.
Apta-qPCR assay for PCa diagnosis. We hypothesized that PCa diagnosis could be improved 
using CG3-aptamer as a capturing molecule prior to a qPCR assay (Fig. 3A). Hence, we developed an 
apta-qPCR assay to detect PCA3 transcripts by using magnetic capture with CG3-aptamer.
Herein, the selected CG3-aptamer was evaluated for its potential clinical utility using the apta-qPCR 
assay, combining the sensitivity of nucleic acid amplification and the selectivity of aptamers21. 
Biotin-labeled CG3-aptamer, immobilized onto streptavidin-coated magnetic beads, was used to cap-
ture the PCA3 conformational RNA molecule, and its ability to bind PCA3-277 asymmetric PCR frag-
ments was tested in serial dilutions of the transcript. The binding efficiency of aptamer was evaluated 
based on the amount of PCA3-277 recovered by elution and quantified by qPCR. Our data demon-
strated that the reaction efficiency and linearity was consistent. The calibration curve presented 100% 
efficiency (Fig. 3B), and the limit of detection of the PCA3 assay was <102 copies per mL. The amount 
of PCA3 recovered by apta-qPCR was directly proportional to the amount of PCA3 initially incubated 
with biotin-labeled CG3-aptamer, which is an indicator of high affinity and specificity of the aptamer. 
Theoretically, each magnetic bead presents three streptavidin binding sites, allowing three molecules of 
biotin-labeled CG3-aptamer binding (Pierce™ , Thermo Scientific technical information).
To further validate the usefulness of the apta-qPCR assay, specific analyses of PCA3 expression were 
performed in 8 human tissues and 11 peripheral blood samples with a wide linear dynamic range of 
magnitude. After magnetic capture of PCA3 transcript by biotin-labeled CG3-aptamer, the bound PCA3 
was heat-eluted and quantified by qPCR. The limit of quantification (LOQ) was determined by flu-
orescence intensity, according to the concentration of mRNA in the PCR reaction, and comparisons 
between apta-qPCR and direct qPCR in both tissues and blood were performed. All tissue samples were 
PCA3 positive for both apta-qPCR and direct qPCR assays. We have achieved an LOQ 7-fold higher for 
apta-qPCR compared with direct qPCR (p < 0.05) (Fig. 3C). The blood samples that were PCA3 negative 
for direct qPCR analysis (3 out of 11) were successfully detected by the apta-qPCR (sensitivity = 100%). 
The LOQ was 97-fold higher for apta-qPCR compared with direct qPCR (p < 0.05) (Fig. 3D), suggesting 
that aptamer-coupled to magnetic beads is able to capture more molecules than by direct qPCR.
Therefore, the apta-qPCR may significantly improve the sensitivity of PCa diagnosis. BPH patients 
(n = 2) and young healthy individuals used as negative controls (n = 2) were consistently negative in all 
PCR replicates. In addition, the complementary nature of specific sequences of different sizes in the same 
region of PCA3 (277-bp) have been tried, and they only worked as primers, under denatured conditions, 
as observed in conventional PCR reactions. None of the sequences could detect the molecule under 
native conditions. Importantly, other aptamers generated in the same selection have been tested, but with 
lower sensitivity, and specifically BC4 (Supplementary Table 1) were able to capture only half of PCA3 
molecules in comparison with CG3.
The limit of detection has been reported elsewhere22 to be three molecules per PCR reaction, and 
reliable quantification can be performed above the quantification limit of 800 PCA3 mRNA copies per 
milliliter of blood.
To further confirm whether the complete PCA3-277 fragment was fully captured and amplified, all 
amplicons obtained by direct qPCR and also by agarose gel electrophoresis analysis were compared with 
those from apta-qPCR reactions for both tissues and blood (Fig.  3E,F, respectively), (Fig.  3G). Three 
specific fragments were observed and matched the variant sizes and sequences reported by our group 
(unpublished work); 88-bp (gi:87245044), 140-bp (gi:87245043), and 322-bp (gi:87245042). The 88-bp 
fragment was the most frequent amplicon in the apta-qPCR (100% in the blood), but rarely amplified by 
Aptamer 
identification Sequencea
Probe 
unique 
identifiers
Aptamer 
size (ntd)
Number of 
aptamer ntd 
bound to 
PCA3 RNA 
(ntd in bold)
Hybrid 
ΔG
Aptamer-
PCA3 loop 
binding (ntd)
Localization of 
Aptamer-PCA3 
binding (exon / ntd 
position)
CD5 AAGGUCUAUUUCCACACCCUU 15262934 21 14 − 20.0 9 1 (3 to 22 )
DF7 AGAUGUGGUUCUCCAGCCCCUUGCC 15262937 25 18 − 24.0 7 1 (2 to 26 )
BE9 CAUGGUUCCUUCUACAUUUGCCCUAUACCU 15262933 30 10 − 18.1 5 1 (3 to 13 )
BC4* GGUUUAGGUGUGGAUGCCCUUGCU 15262932 24 16 − 20.7 10* 3 (186 to 217 )
CG3* AGUUUUUGCGUGUGUGCCCUUUUUGUCCCC 15262934 30 17 − 19.8 12* 3 (194 to 217 )
DB11 UGCGUUCCCAGAUGUGUCCACCGGA 15262936 25 15 − 18.5 9 3 (200 to 218 )
Table 1.  Description of the six best aptamer sequences against PCA3. (*)Aptamers chosen for ISH assay. 
(a)Motifs were underlined in the sequences.
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Figure 3. (A) Schematic overview of the apta-qPCR approach. (B) Standard curve constructed using 107 
to 102 copies/μ L of PCA3. Data were obtained from six independent experiments with duplicate samples at 
four time points, and show high PCR reproducibility and efficiency. Comparisons of direct qPCR and apta-
qPCR in tissue (C) and blood (D) samples. PCA3 levels (copies/μ L) calculated for tissue (E) and blood (F) 
samples. (G) Agarose gel electrophoresis analysis of PCA3 amplicons. Red arrows indicate PCA3 variant 
sizes. Lanes 1 and 4 = direct qPCR for tissue samples; lanes 8, 10 and 12 = direct qPCR for blood samples; 
lanes 2, 5 and 11 = apta-qPCR for tissue samples; lanes 3, 6, 7 and 9 = apta-qPCR for blood samples. 
M = 100-bp ladder.
www.nature.com/scientificreports/
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direct qPCR. Therefore, the fluorescence intensity obtained in the real-time qPCR corresponded to the 
sum of fluorescence signals of any amplified fragment in each reaction. PCA3 variants observed may be 
an indication that lncRNA is processed after transcription.
Aptamers as histological probe for PCa detection. Representative images of tissues with 
CG3-aptamer staining are shown in Fig. 4. Biotin-labeled CG3-aptamer was most frequently (78%) local-
ized in the nucleus of BPH cells (Fig.  4A,B2), while it was equally distributed in both cytoplasm and 
nucleus of PCa cells (Fig. 4B3) and absent in stromal cells.
Figure 4. (A) Immunoreactivity score (0 to 3) for biotin-labeled CG3-aptamer probe in a tissue microarray 
(TMA) of BPH and PCa samples. Representative in situ hybridization detection of TMA samples (400× ). 
(B1) Normal prostate tissue; (B2) BPH case with strong nuclear and weak cytoplasmic staining; (B3) PCa 
case with nuclear and moderate cytoplasmic staining; (C) Lymphoma; (D) Gastric cancer and (E) Pancreatic 
cells.
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We observed a homogeneous nuclei-cytoplasm staining of prostatic adenocarcinoma specimens, 
probably due to a constant PCA3 RNA production and processing. We were unable to discriminate 
prostate tumor stages by differential staining intensity.
To determine whether biotin-labeled CG3-aptamer was specific to prostate tissues, we investigated 
other tumors. In fact, 100% of a lymphoma (Fig.  4C) and gastric cancers (Fig.  4D) tissue specimens 
stained negatively in both nucleus and cytoplasm. The pancreatic tumor cells (Fig. 4E) presented negative 
labeling at nuclei, and a very weak cytoplasmic staining (33%) (Table 2).
As previously mentioned, the molecules detected by apta-qPCR consisted of variable transcript sizes 
(Fig. 3G) suggesting a possible PCA3 post-transcriptional processing, which may occur inside the nucleus.
Aiming to demonstrate whether CG3-aptamer binds to a specific DNA conformation in the nucleus, 
we used total non-denatured DNA from PCa and BPH patients as targets for biotin-labeled CG3-aptamer, 
and performed an apta-qPCR, which resulted in no amplification. Therefore, an explanation for the lack 
of PCA3 amplification (qPCR) in both prostate tissues and blood from most BPH patients must still be 
uncovered.
Discussion
This is a proof-of-concept study of PCA3 gene, a long non-coding transcript overexpressed in more than 
95% of primary PCa tissue specimens13 and the first PCa specific biomarker14.
Specific RNA binding is dependent on both sequence and structure of the folded molecule. Our 
hypothesis about base pair aptamers was that it could be selected against the folded molecule either 
by regular Watson-Crick associations with non-folded single strands or by interacting with the confor-
mational structure. The immobilization of the single-stranded DNA molecule from a 277-nt fragment, 
which may have partially paired and bound to the PCA3 RNA conformational structure, onto magnetic 
beads was able to expose more accessible “aptatopes” for the interaction with the RNA library, and a 
highly specific aptamer was successfully selected.
Regarding the aptamer selection against ssDNA, we understand that despite the chemical similarity 
of RNA and DNA backbones, there is evidence from X-ray crystallography that the identity of sugar 
(ribose vs. deoxyribose) affects backbone conformations23. Although researchers have used the properties 
of DNA to understand RNA folding24 and previous measurements of flexible single-stranded nucleic 
acids25–27, they have not reached a consensus about conformations. Chen et al. demonstrated that ssDNA 
and ssRNA present differences in conformation while nucleic acids lack secondary structures28. However, 
the same authors have also shown that the effect of the local environment on chain flexibility, in the 
presence of a flanking double-stranded helix, affects the conformation of single-stranded regions, with 
implications for biologically relevant nucleic acids. Unfortunately, similar analyses of flexible and disor-
dered regions are still confusing due to the lack of full knowledge on backbone conformations in solu-
tion, and how they depend on base content, sugar type, and the presence of salt ions28, as have been also 
shown by different RNA folding softwares (M-fold, S-fold, UNAfold, and others). Due to the stability 
problems of PCA3 RNA during the selection process, we have hypothesized that ssDNA could share at 
least partial conformational structures with ssRNA due to the extensive base-pairing observed inside the 
PCA3 molecule. Therefore, we used ssDNA for stability. The enrichment of specific aptamers has later 
proved that aptamer binds exclusively to PCA3 mRNA, as shown by specific PCR assays against PCA3 
negative RNA, PCA3 positive RNA, and DNA.
The identification of trimmed molecules that led to the development of the six aptamers was restricted 
to the minimal target-binding domain, which has been successfully carried out by alignment. Functional 
aptamers with less than 40-nucleotides long were obtained, as described elsewhere29–34. In general, fixed 
sequence regions used for primer binding are unimportant for aptamer function and can be eliminated. 
Advances in aptamer design have been made to eliminate the requirement for the fixed regions in ran-
dom sequence libraries during the SELEX process, thereby producing short aptamer sequences35.
Tissue type
Sample 
size
Stained nucleus (%) Stained cytoplasm (%)
Negative
Positive
Negative
Positive
Weak Moderate Strong Weak Moderate Strong
BPH 23 13 – 9 78 61 30 9 –
Prostatic adenocarcinoma T2 68 21 15 41 24 28 25 35 12
Prostatic adenocarcinoma 
T3 – T4 61 11 26 44 18 25 28 34 13
Lymphoma 3 100 – – – 100 – – –
Gastric cancer 3 100 – – – 100 – – –
Pancreatic cancer 3 100 – – – 67 33 – –
Table 2.  Summary of tissue stained with CG3-aptamer probe.
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The binding properties of aptamers are due to the formation of specific aptamer/target complexes sta-
bilized by non-covalent interactions. The binding of the aptamer to its cognate target triggers an adaptive 
folding, in which the target promotes and stabilizes the secondary and tertiary aptamer structures36. It 
can be clearly seen that RNA bases involved in molecular recognition do not form Watson–Crick base 
pairs, as has been predicted for our CG3-aptamer, demonstrated in Fig.  1. A similar conclusion was 
reached by Carothers et al.35, who demonstrated secondary structures for 11 classes of GTP aptam-
ers. Bases with high informational content, which are important for high-affinity binding, are always 
unpaired and located in loops or bulges. There are two possible reasons for this: first, unpaired RNA 
bases are more flexible, so they can easily change their conformation to form a binding pocket and 
accommodate a ligand, and second, unpaired bases have available donor or acceptor atoms for potential 
formation of hydrogen bonds with the ligand20. Therefore, following our aptamer selection criteria, we 
found that the predicted secondary structure of CG3-aptamer (30 bases) may present at least 26 unpaired 
bases. It has been suggested that the optimum stability of aptamers is obtained with seven complemen-
tary bases20, and the greater the number of unpaired bases the lower the possibility to form secondary 
structures with high free energy. Conversely, the greater the self-folding through aptamer base-pairs the 
lower their binding affinity. Interestingly, the two most frequent motifs found in our sequences, UGCC 
and UGUC, were present within the unpaired bases of CG3-aptamer.
Recent studies have shown that aptamers may greatly benefit PCa diagnosis and treatment. At dif-
ference from antibodies, aptamers can be generated as molecular beacons or may be conjugated with a 
variety of functional tags, adapting to many assay formats without losing activity. Thus, taking advantage 
of their nucleic acid nature, apta-qPCR assays have been developed. Apta-qPCR uses the dual function 
of aptamers, acting both as a selective ligand to target molecules and as a template for qPCR2. Thrombin 
detection was one of the first targets of an apta-qPCR assay, which has reached as low as a few hundred 
fM37. E. coli detection with a mixture of antibody and aptamer followed by qPCR amplification was able 
to detect ten bacterial cells per mL38.
Currently, there are only two aptamers developed against proteins involved in PCa. The first and best 
characterized PCa related aptamer is A10, which binds the prostate-specific membrane antigen (PSMA), 
a tissue marker associated with the beginning and progression of PCa39. However, its utility in PCa 
diagnosis is not clear, and its use has been restricted to in vitro inhibition of PSMA. The second one is 
an unmodified RNA aptamer selected against the recombinant prostate-specific antigen (PSA) which 
was able to distinguish between the active and inactive forms of the enzyme40, but its diagnostic utility 
is questionable. Furthermore, PSA has severe limitations for PCa detection due to its low specificity and 
low negative predictive value41. This fact has been reinforced by The United States Preventive Services 
Task Force that issued their final recommendation on PSA prostate cancer-screening test recommending 
against routine PSA exams for men of any age34.
Currently, the FDA-approved PCA3 detection in the urine after intense prostatic massage is one of 
the best available PCa biomarkers with proven utility in the detection and management of early PCa41 
Similar accuracy has been achieved in peripheral blood42, a much less invasive procedure. Therefore, the 
focus on PCA3 expression is justified, and aptamers that bind to the native conformation of lncPCA3 
transcript become a much more interesting target than the simple Watson-Crick base-pairing of either 
PSA or PSMA transcripts. This investigation reports the evolution of RNA aptamers against the confor-
mational structure of lncRNA, which could bind to the native folded structure under physiological con-
ditions, without denaturation. An apta-qPCR assay was further developed by a magnetic capture system 
followed by qPCR amplification and detection of PCA3 transcripts in blood, which proved to be a very 
useful tool for PCa diagnosis with excellent sensitivity (100%). We further tested the CG3-aptamer probe 
in histopathologic assays that also corroborated our findings, evidencing specific and differential staining 
patterns in PCa and BPH tissue samples.
Aptamers are versatile tools that rival antibodies in diagnostic applications. A classic example of this 
property is evidenced by an RNA aptamer selected against the constant region (Fc) of the rabbit IgG, 
which is used as a reporter and may be a secondary marker in several assays where rabbit IgG antibodies 
are used43. Unlike antibodies, synthetic aptamers can easily be produced with a high degree of accuracy, 
reproducibility and purity. Therefore, little or no batch-to-batch variation is expected in aptamer pro-
duction. They are not sensitive to temperature and undergo reversible denaturation, thus having a much 
longer shelf life. Furthermore, the specificity of aptamer recognition may be able to discriminate cognate 
target molecules and related structures by more than 10.000 to 12.000-fold44.
The stronger CG3-aptamer positivity staining in the nuclei of BPH cells suggests that PCA3 RNA 
generated in the nucleus might be degraded or have not yet been processed before being exported to the 
cytoplasm. The diminished PCA3 expression in the cytoplasm of BPH cells might be due to the loss of 
these transcripts, and the weaker positive staining may be an indication of the early development of a 
microfocal tumor event without morphological alterations.
Our histological findings in PCa tissues, demonstrating that PCA3 is detected in both nucleus and 
cytoplasm, may explain some of the contrasting results for the subcellular location of PCA3, which has 
been observed at the nucleus15,45, at microsomal subcellular fractions15, and at the cytoplasmic compart-
ment45, but not in prostate-tumor stromal cells15. We believe that discordances on sensitivity and location 
of PCA3 are due to the short splice variants found in both nucleus and cytoplasm, with a predominance 
www.nature.com/scientificreports/
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of short transcripts at the cytoplasm, which cannot be detected by primers that are not properly designed 
because of the extensive variation of PCA3 transcript sequences.
A brief analysis of 88-bp and 140-bp sequences indicated that fragments are only partially transcribed, 
specifically for exons 1 and 4 (88-bp), and 1, 3 and 4 (140-bp), regions that matched the predicted folded 
structure of the PCA3-277 fragment presented in Fig. 1. The only explanation for partial fragments does 
not rely on an editing process, but in a folded structure that may suffer specific processing and/or cleav-
age. It is still not known how PCA3 fragments act by modulating AR signaling and controlling PCa cell 
survival15; however, considering our histological findings of PCA3 staining in tumor tissues, increased 
cytoplasmic staining suggests that these fragments might favor tumor occurrence. In addtion, we cannot 
discard the possibility that such fragments might be precursors of regulatory microRNAs. PCA3 is clearly 
absent in normal tissues where transcription is negligible, and the strong staining within the nucleus 
of BPH tissues may be due to the unprocessed PCA3, which is not related to DNA folding because 
the CG3-aptamer could not bind to the native conformation of DNA molecules. This result raises the 
possibility that part of the elevated concentration of intranuclear PCA3 is caused by faulty processing.
In summary, we have demonstrated by in silico analysis that the PCA3 transcript molecule undergoes 
a significant folding with many hairpins and loops, resulting in a free energy conformational structure. 
This predicted arrangement might suffer in the nucleus specific post-transcriptional processing during 
tumor development, exporting smaller folded base-paired fragments to the cytoplasm that may modulate 
other genes, including the androgen receptor signaling pathway. Such findings were possible due to the 
development of CG3-aptamer, which was evolved against 277-bases of PCA3 transcript with high affin-
ity under physiological conditions. This specific aptamer was used in the development of an apta-qPCR 
assay that captured and amplified PCA3 transcripts 97-fold and 7-fold higher than conventional qPCR 
in blood and tissue, respectively. This aptamer was also successfully used for histopathologic analysis 
through “in situ hybridization” using physiological conditions without denaturation with great sensitivity 
and specificity. Further analysis of apta-qPCR by using agarose gel electrophoresis identified specific and 
smaller fragments that matched the PCA3-277 transcript region encompassing parts of the exons 1, 3 
and 4, which may be derived from additional RNA processing. Potential novel therapeutic and diagnostic 
uses of this aptamer are under investigation.
Patients and Methods/Material
Aptamer selection. Immobilized target molecule. Selection of RNA aptamers with high affinity and 
specificity to PCA3 RNA was performed against single-stranded DNA molecule from 277-nt fragment, 
which may have partially paired and bound to PCA3 RNA conformational structure, encompassing parts 
of exons 1, 3 and 4 (alternative splicing of exon 2), which is the most common transcript detected in 
95% of PCa tissues13.
Briefly, PCA3-277 PCR fragment was cloned and purified as previously reported46, and biotin was 
incorporated at the 5′ - sense strand of PCA3-277 during asymmetric PCR amplification, using 5 pmols 
of biotinylated forward-primer (5′ biotin - AGATGTTCTTTGATGCGGAGC - 3′ ), the GeneAmp® 
dNTPs with dUTP and TaqMan® Universal PCR Master Mix (Applied Biosystems), which, containing 
AmpErase® UNG, protects against subsequent re-amplification from PCR products containing dUTP 
to minimize carry-over contamination. UNG incubation at 50 °C was used to cleave any dU‐containing 
PCR carryover products, and 10 min incubation at 95 °C was used to inactivate the UNG activity, and to 
denature the native DNA in the experimental sample. PCR assay was performed as previously reported47, 
with minor modifications.
Genomic SELEX. For the library construction, we used 1 μ g of a pool of genomic DNAs from human 
PCa tissue specimens (PCA3-277 positive). All PCa patients were submitted to radical prostatectomy. 
The library was generated by random priming of sonicated DNAs, followed by sizing to obtain overlap-
ping fragments of any desired size. The library construction was performed as described elsewhere5,48.
The in vitro transcription of the RNA pool from the library was performed by T7 RiboMAX™ , 
according to manufacturer instructions (Promega). The SELEX was performed using 400 pmols of 
single-stranded biotinylated PCA3-277 (bait uracil) incubated with 10 nmols of estimated 1014 RNA 
aptamers.
PCR products with genome-specific biotinylated primer were batch-purified on streptavidin-coated 
magnetic beads (Pierce™ - Thermo Scientific). A fresh aliquot of 1 × 108 streptavidin beads was 
washed 3 times with binding buffer (with 0.02% of Tween 20) before each selection round. The pool of 
single-stranded biotinylated PCA3-277 was heated to 55 °C for 10 min, immediately cooled, and kept at 
4 °C for 15 min, followed by a short incubation (5 min) at room temperature before its application in the 
binding reaction. The in vitro selection strategy was designed to identify aptamers that could bind the 
target under physiological conditions, so aptamers were bound to PCA3-277 at 37 °C (pH 7.4) for one 
hour under gentle shaking. The bead:PCA3-277 complex was washed four times with binding buffer to 
remove non-specific binding. Oligonucleotides complementary to biotinylated single strand were eluted 
two times by denaturation with NaOH (0.15 M) at 37 °C, for 10 min. The oligonucleotides were precipi-
tated with ethanol, and then resuspended in a smaller volume of binding buffer.
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During this SELEX process the selected RNA of each round was reverse-transcribed and subsequently 
amplified by RT-PCR, using fix-REV and fix-FOR primers. The new RNA pool for the next SELEX round 
was then generated again by in vitro transcription (Fig. 5B).
To monitor the enrichment of the selected aptamer pool from SELEX rounds 1, 3 and 8 the sequences 
were amplified and cloned into pCR2.1-TOPO vector systems (Invitrogen). The purified sequences 
(192 clones per round) were submitted to sequencing (MegaBace 1000), using the DYEnamic Dye 
Terminator Cycle Sequencing kit (GE Healthcare), and after alignment the sequences were clustered 
according to repeated motifs. These were identified using the Clustal software package of the GCG suite of 
molecular biology programs. Three sequencing reactions were carried out for each fragment and injected 
twice to minimize sequencing artifacts.
Criteria to evaluate candidate aptamers. The criteria to generate a list of potential RNA aptamers from 
the 8th selection round consisted of three steps: (1) selection of sequences based on motifs; (2) sequences 
sizes up to 21 nucleotides long; and (3) significant hybridization energy characteristics between the 
folded-structure of PCA3-277 transcript and selected aptamers (Δ Ghybrid ≤ − 18.0 kcal/mol). RNAhybrid, 
an extension of the classical RNA secondary structure prediction algorithm19, was used for hybridization 
and nucleic acid folding predictions. The secondary structure analysis was performed by free-energy 
minimization.
Apta-qPCR for quantitative detection of PCA3-277. Ethics statement. This procedure was 
approved by the UFU Research Ethics Committee (approval number 562.678/2013), along with the 
Urology Service of the University Hospital. All experiments were performed in accordance with relevant 
guidelines and regulations.
Figure 5. (A) Construction of a random DNA oligonucleotide library. Genomic DNA was size-fractionated, 
size-selected, and PCR amplified to generate the genomic library. Two hybrid primers (hyb) consisting of 
nine random nucleotides (red) followed by specific sequences (light and dark blue, fix primers) were used 
to specifically amplify the library. After synthesis, reaction products are size-selected by gel electrophoresis. 
The fraction that contains library fragments of the desired size range is eluted and amplified by PCR with 
the fix-primer pair. The T7 promoter (dashed line) for transcription of the library into RNA is incorporated 
in the fix-FOR primer sequence, according to Zimmermann et al.5 with minor modifications. (B) Schematic 
representation of the genomic SELEX, according to Stoltenburg et al.1 with modifications. Streptavidin-
coated magnetic beads coupled to biotinylated PCA3 were used to select RNA aptamers, forming a 
target:aptamer complex. The SELEX procedure consisted of eight cycles of selection steps: binding, washing, 
elution, amplification and purification. A newly enriched pool of selected oligonucleotides was generated 
by preparation of the relevant ssDNA for in vitro transcription. The enriched aptamer pool was cloned, and 
several individual aptamers were characterized by sequencing.
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Patients and sample. All patients gave informed consent before specimen collection. Tissue fragments 
were obtained from 8 PCa patients and frozen in − 80 °C before RNA extraction.
Peripheral blood samples were collected before surgery in a vacutainer™ tube containing K2EDTA 
7.2 mg, and maintained at 4 °C. Blood samples from 13 patients were grouped into two classes: 11 with 
PCa and 2 with benign prostatic hyperplasia (BPH), according to histological classification of tissues. 
BPH patients were submitted to transurethral resection of prostate (TURP). All PCa patients were sub-
mitted to radical prostatectomy. Blood from two young individuals were used as negative controls.
Total RNA extraction from tissue samples was performed as described elsewhere42 RNA yield and 
A260/280 ratio were monitored using a NanoDropND-100 spectrometer (NanoDrop Technologies). For 
the apta-qPCR approach, 1 μ g of total RNA was used from each sample.
Apta-qPCR. Synthetic biotinylated anti-PCA3 aptamers (CG3-aptamer; GenBank/PUIDs: 15262935) 
were synthesized by Integrated DNA Technology (IDT). Each sample was incubated with 200 pmols of 
biotin-labeled CG3-aptamer in binding buffer for 30 min, at 37 °C. The biotinylated-CG3:RNA complex 
was incubated with pre-washed 1 × 104 streptavidin-coated magnetic beads at 37 °C, for 30 min, with 
mild shaking. Unbound single-stranded RNA sequences were removed by washing three times to remove 
non-specific binding. The bound RNA was heat-eluted in ultrapure water at 95 °C, for 15 min, and used 
as template for qPCR amplification.
The amount of RNA PCA3-277 molecules recovered in each sample was transcribed and quantified 
by absolute qPCR. To demonstrate the functionality of CG3-aptamer, the results of the apta-qPCR assay 
was compared with direct qPCR in all samples. Additionally, as positive control, serial dilutions (4 × 1014, 
2 × 1014, 0.9 × 1014 and 0.5 × 1014 molecules) of single-stranded PCA3-277 asymmetric PCR fragment 
(without biotin-labeled) were incubated with biotin-labeled CG3-aptamer, recovered and monitored by 
qPCR, as previously described above.
Construction of standard curve. The 277-bp PCA3 amplicon was cloned and used to establish the 
standard curve, as described elsewhere46, with serial dilutions of 107, 106, 105, 104, 103 and 102 copies 
of PCA3 gene. Linearized plasmid was quantified by spectrophotometry and the number of molecules 
was estimated according to the formula: copies/μ L = [6.023 × 1023 × C × OD260 / MW] × 10−3, where 
C = 5 × 10−5 g/mL and MW (molecular weight) for PCA3 = 277 × 658. Absolute quantification was 
obtained by qPCR carried out in an ABI PRISM 7300 sequence detection system (Applied Biosystems); 
information on the PCR reaction condition is available on request. The difference between the threshold 
cycles (Ct) obtained for PCA3 mRNA (Δ Ct) was determined and the results were calculated from the 
log-linear relationship between the base-10 logarithm of PCA3 mRNA copy number and Δ Ct49.
Tissue microarrays and in situ hybridization. Tissue samples were provided by the AC Camargo 
Hospital Tumor Bank (São Paulo, Brazil). For in situ hybridization (ISH), we evaluated a total of 161 
cases, including 129 PCa, 23 BPH, 3 lymphomas, 3 gastric cancers, and 3 pancreatic cancers. The median 
patient age was 63 (46–86) years.
Tissue fragments of 1 mm were obtained from PCa and BPH patients to assemble a tissue microarray 
(TMA; Beecher Instruments, Sun Prairie/WI) as previously described50. Biotin-labeled CG3-aptamer was 
used to detect PCA3-277 transcript by ISH analysis.
For ISH reactions, tissue slides were incubated with 1 μ g of biotin-labeled CG3-aptamer at 37 °C, 
for one hour. Slides were washed 3 times with PBS and incubated with horseradish peroxidase (HRP)- 
streptavidin-conjugated for 5 min. After three more washes using PBS, slides were incubated with the 
peroxidase substrate, and washed twice using PBS. The slides were counter-stained in Mayer’s hematox-
ylin for 60 sec, blued with tap water, dehydrated, cleared, and mounted for light microscopy. Endogenous 
ISH result
Staining 
intensity
Fraction of stained 
tumor cells (%)
Negative No staining
Weak positive* 1+ ≥ 10 < 50
2+ ≥ 10 < 30
Moderate positive* 1+ ≥ 50
2+ ≥ 30 < 60
3+ ≥ 10 < 50
Strong positive* 2+ ≥ 60
3+ ≥ 30
Table 3.  Histopathologic scoring criteria for CG3-aptamer probe staining. *Positive score: ≥ 10% of 
stained tumor cells.
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biotin was blocked with avidin-biotin-complex kit (DAKO). Histochemical reactions were performed 
simultaneously to avoid any bias in the results, due to differences in environmental conditions. The 
CG3-aptamer probe staining was visually evaluated in both PCa and BPH TMA spots. Percentage of 
positive cells and staining intensity (scores from 1 to 3) were recorded for each tissue spot. Staining was 
then categorized as described in Table 3.
Statistical analysis. PCA3 expression between two groups was compared using Mann-Whitney’s 
U-test or the Fisher’s exact test, when appropriate. Results are presented as the mean + /- standard devia-
tion of at least three independent experiments. Probability values below 0.05 were considered statistically 
significant. Data were analyzed using GraphPad Prism software (San Diego-CA, USA).
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